Institution scientifique

Biogen (United Kingdom)

Maidenhead · GB · company

251Publications signalées

8972Citations signalées

12Thèmes principaux

Principaux domaines

Multiple Sclerosis Research StudiesBiosimilars and Bioanalytical MethodsNeurogenetic and Muscular Disorders ResearchHealth Systems, Economic Evaluations, Quality of LifeAmyotrophic Lateral Sclerosis ResearchPharmaceutical studies and practicesRheumatoid Arthritis Research and TherapiesRNA modifications and cancerMonoclonal and Polyclonal Antibodies ResearchInflammatory Bowel DiseaseInterstitial Lung Diseases and Idiopathic Pulmonary FibrosisAcute Lymphoblastic Leukemia research

Évolution annuelle

1889 1

1987 1

1998 1

1999 1

2000 1

2002 1

2003 2

2007 3

2008 3

2009 3

2010 4

2011 2

2012 3

2013 7

2014 6

2015 6

2016 12

2017 12

2018 12

2019 26

2020 33

2021 24

2022 23

2023 20

2024 13

2025 10

2026 6

Publications récentes

2026 articleOpenAlex

Efficacy and safety of the CD40 ligand inhibitor dapirolizumab pegol in systemic lupus erythematosus (PHOENYCS GO): a randomised, double-blind, placebo-controlled, phase 3 trial

Megan E B Clowse, David A Isenberg, Joan T Merrill, Thomas Dörner et autres

4 citationsThe Lancet

Accès ouvert 2026 erratumOpenAlex

Author Correction: High-dose nusinersen for spinal muscular atrophy: a phase 3 randomized trial

Richard S. Finkel, Thomas O. Crawford, E Mercuri, Charlotte J. Sumner et autres

1 citationNature Medicine

Accès ouvert 2026 articleOpenAlex

First-in-Human Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Oral Doses of BIIB091, an Oral BTK Inhibitor, in Healthy Adult Participants

Hui-Hsin Tsai, Yi Gu, Katherine Riester, Sherman Chu et autres

0 citationsDrug Design Development and Therapy

2026 articleOpenAlex

Unlocking the potential of disease prevention through regulatory science

Daniel J. O’Connor, Alison C. Cave, Alejandro F. Frangi, John Hardy et autres

0 citationsNature Reviews Drug Discovery

Accès ouvert 2026 articleOpenAlex

High-dose nusinersen for spinal muscular atrophy: a phase 3 randomized trial

Richard S. Finkel, Thomas O. Crawford, Eugenio Mercuri, Charlotte J. Sumner et autres

10 citationsNature Medicine

Accès ouvert 2026 articleOpenAlex

Long-Term Tofersen in SOD1 Amyotrophic Lateral Sclerosis

Timothy M. Miller, Merit Cudkowicz, Pamela Shaw, Angela Genge et autres

28 citationsJAMA Neurology

Accès ouvert 2025 articleOpenAlex

Long-term tofersen in SOD1 amyotrophic lateral sclerosis

T.M. Miller, M.E. Cudkowicz, P.J. Shaw, A. Genge et autres

0 citationsWhite Rose Research Online (University of Leeds, The University of Sheffield, University of York)

Accès ouvert 2025 articleOpenAlex

Open-label phase IV trial evaluating nusinersen after onasemnogene abeparvovec in children with spinal muscular atrophy

Crystal M. Proud, Richard S. Finkel, Julie Parsons, Riccardo Masson et autres

7 citationsJournal of Clinical Investigation

2025 articleOpenAlex

24ODEVOTE part C results: exploring higher doses of nusinersen in nusinersen-experienced participants with spinal muscular atrophy (SMA)

E. Mercuri, Thomas O. Crawford, R. Finkel, John Day et autres

0 citationsNeuromuscular Disorders

2025 articleOpenAlex

422PNURTURE study: long-term benefits of nusinersen in presymptomatic spinal muscular atrophy (SMA) over 8 years of Follow-up

N. Kuntz, D. De Vivo, T. Crawford, J. Kirschner et autres

1 citationNeuromuscular Disorders

Accès ouvert 2025 articleOpenAlex

Optimizing Patient Registries for Regulatory Decision Making ‐ Key Learnings From an HMA / EMA Multistakeholder Workshop

Kelly Plueschke, Carla J. Jonker, Hanna Kankanen, Thorsten Vetter et autres

15 citationsClinical Pharmacology & Therapeutics

Accès ouvert 2025 conference-abstractOpenAlex

POS0734 DAPIROLIZUMAB PEGOL DEMONSTRATED SIGNIFICANT IMPROVEMENT IN SYSTEMIC LUPUS ERYTHEMATOSUS DISEASE ACTIVITY: EFFICACY AND SAFETY RESULTS OF A PHASE 3 TRIAL

Edward M Vital, M.E.B. Clowse, David Isenberg, J. Merrill et autres

1 citationAnnals of the Rheumatic Diseases

Site officiel Identifiant ROR

BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, ROR et la Banque mondiale, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune donnée externe enregistrée en base. Sources et limites.